UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Medline ® Abstract for Reference 5

of 'Medical treatment for relapsed epithelial ovarian, fallopian tubal, or peritoneal cancer: Platinum-resistant disease'

5
TI
Salvage chemotherapy with paclitaxel in platinum-resistant advanced ovarian cancer patients.
AU
Bruzzone M, Catsafados E, Miglietta L, Amoroso D, Pedulla F, Giannessi PG, Locatelli MC, D'Antona A, Foglia G, Mammoliti S, Turno F, Gentile A, Nicosia F, Luporini G, Ragni N, Boccardo F
SO
Oncology. 1996;53(5):349.
 
Encouraging results with Paclitaxel are reported in ovarian cancer patients relapsing and progressing after platinum-based chemotherapy; however, the two populations have different probabilities of a response to a second-line treatment. Here we report the results achieved in 39 patients with platinum-refractory ovarian cancer, treated with Paclitaxel 175 mg/qm2 (or 135 mg/m2 if heavily pretreated) using 3-hour intravenous infusion every 3 weeks, in an attempt to verify the activity of this drug in platinum-resistant patients. The toxicity was mild to moderate and primarily hematologic and neurologic. The objective response rate is 12.8% with no complete responses. The response duration was brief and the median survival 6 (range 1-17) months. An accurate cost-benefit balance is necessary before routinely use of Paclitaxel in platinum-refractory patients. Further research is needed to determine the optimal role of Paclitaxel in the whole therapeutic strategy for ovarian cancer.
AD
Department of Medical Oncology 2, National Institute for Cancer Research, Pisa, Italy.
PMID